PGE2 upregulates renin through E-prostanoid receptor 1 via PKC/cAMP/CREB pathway in M-1 cells

Am J Physiol Renal Physiol. 2017 Oct 1;313(4):F1038-F1049. doi: 10.1152/ajprenal.00194.2017. Epub 2017 Jul 12.

Abstract

During the early phase of ANG II-dependent hypertension, tubular PGE2 is increased. Renin synthesis and secretion in the collecting duct (CD) are upregulated by ANG II, contributing to further intratubular ANG II formation. However, what happens first and whether the triggering mechanism is independent of tubular ANG II remain unknown. PGE2 stimulates renin synthesis in juxtaglomerular cells via E-prostanoid (EP) receptors through the cAMP/cAMP-responsive element-binding (CREB) pathway. EP receptors are also expressed in the CD. Here, we tested the hypothesis that renin is upregulated by PGE2 in CD cells. The M-1 CD cell line expressed EP1, EP3, and EP4 but not EP2. Dose-response experiments, in the presence of ANG II type 1 receptor blockade with candesartan, demonstrated that 10-6 M PGE2 maximally increases renin mRNA (approximately 4-fold) and prorenin/renin protein levels (approximately 2-fold). This response was prevented by micromolar doses of SC-19220 (EP1 antagonist), attenuated by the EP4 antagonist, L-161982, and exacerbated by the highly selective EP3 antagonist, L-798106 (~10-fold increase). To evaluate further the signaling pathway involved, we used the PKC inhibitor calphostin C and transfections with PKCα dominant negative. Both strategies blunted the PGE2-induced increases in cAMP levels, CREB phosphorylation, and augmentation of renin. Knockdown of the EP1 receptor and CREB also prevented renin upregulation. These results indicate that PGE2 increases CD renin expression through the EP1 receptor via the PKC/cAMP/CREB pathway. Therefore, we conclude that during the early stages of ANG II-dependent hypertension, there is augmentation of PGE2 that stimulates renin in the CD, resulting in increased tubular ANG II formation and further stimulation of renin.

Keywords: CREB; gene expression; kidney; prostaglandin E2; protein kinase C.

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Animals
  • CREB-Binding Protein / genetics
  • CREB-Binding Protein / metabolism*
  • Cell Line
  • Cyclic AMP / metabolism*
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Dinoprostone / pharmacology*
  • Dose-Response Relationship, Drug
  • Kidney Tubules, Collecting / drug effects*
  • Kidney Tubules, Collecting / enzymology
  • Mice
  • Molecular Docking Simulation
  • Phosphorylation
  • Prostaglandin Antagonists / pharmacology
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase C / genetics
  • Protein Kinase C / metabolism*
  • Protein Kinase Inhibitors / pharmacology
  • RNA Interference
  • Receptors, Prostaglandin E, EP1 Subtype / agonists*
  • Receptors, Prostaglandin E, EP1 Subtype / genetics
  • Receptors, Prostaglandin E, EP1 Subtype / metabolism
  • Receptors, Prostaglandin E, EP3 Subtype / metabolism
  • Receptors, Prostaglandin E, EP4 Subtype / metabolism
  • Renin / genetics
  • Renin / metabolism*
  • Renin-Angiotensin System / drug effects*
  • Signal Transduction / drug effects
  • Transfection
  • Up-Regulation

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Prostaglandin Antagonists
  • Protein Kinase Inhibitors
  • Ptger1 protein, mouse
  • Ptger3 protein, mouse
  • Ptger4 protein, mouse
  • Receptors, Prostaglandin E, EP1 Subtype
  • Receptors, Prostaglandin E, EP3 Subtype
  • Receptors, Prostaglandin E, EP4 Subtype
  • Cyclic AMP
  • CREB-Binding Protein
  • Crebbp protein, mouse
  • Cyclic AMP-Dependent Protein Kinases
  • Protein Kinase C
  • Renin
  • Dinoprostone